PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Status:
Terminated
Trial end date:
2020-04-17
Target enrollment:
Participant gender:
Summary
This will be a randomized double blind placebo-controlled pilot study using a repeated
measures design in which participants with acute ischemic stroke and intracranial
atherosclerotic disease are randomized to either drug or placebo.